Centanafadine is a medicine used to treat ADHD in adults and children 6 and older. It is taken as a capsule by mouth. It works by raising the levels of brain chemicals that help with focus and attention.
Every report comes from a Lived member, sent anonymously.
Have you tried Simtriyo (Centanafadine) for ADHD?
Centanafadine, under the brand name Simtriyo, is a prescription medicine for attention-deficit/hyperactivity disorder (ADHD) in adults and in children 6 and older who weigh at least 20 kg (about 44 pounds). ADHD involves persistent trouble with attention, restlessness or impulsivity that gets in the way of school, work or relationships. Centanafadine is not recommended for children younger than 6, who lost more weight on it in studies, or for children under 20 kg, for whom there is too little data. It is a new kind of ADHD medicine. It affects three of the brain's chemical messengers, including serotonin, and the US Food and Drug Administration (FDA) classifies it as a central nervous system stimulant, the same broad safety category as other stimulant ADHD medicines. The FDA approved Simtriyo in July 2026. Because it is a stimulant, it can only reach pharmacies after the Drug Enforcement Administration (DEA) decides which controlled-substance category it belongs in. As of late October 2026 that decision was still pending, so the medicine is not yet available to fill.
Nerve cells in the brain pass signals to one another using chemical messengers. After a messenger delivers its signal, the sending cell normally pulls it back in, a process called reuptake. Centanafadine blocks the reuptake of three messengers: norepinephrine, dopamine and serotonin. More of each stays available to carry signals between cells. The prescribing information is candid that exactly how this improves ADHD is not known; the effect on these three messengers is the likely explanation rather than a proven one. The capsule releases the medicine gradually, with blood levels peaking about five hours after a dose, so a single morning dose is designed to cover the day.
Simtriyo is an extended-release capsule taken once a day in the morning, at about the same time each day, with or without food. It comes in 140 mg, 210 mg and 280 mg strengths. Adults usually start at 210 mg, and the prescriber may raise the dose to 280 mg depending on how well it works and how it is tolerated. Teens 13 to 17 take 280 mg, and children 6 to 12 take a dose set by body weight. In the children's and teen studies a lower dose did not work better than placebo, which is why these are the recommended amounts. The capsule should not be cut, crushed or chewed, because it is built to release the medicine slowly. It can be swallowed whole, or opened and the entire contents sprinkled on a tablespoon of applesauce or yogurt or stirred into a tablespoon of orange juice. The mixture should be taken right away, followed by water, without chewing the granules or saving any for later. A missed dose can be taken up to 4 hours after the usual time; later than that, skip it and continue the next morning. Never take more than one dose in a day. If someone takes too much, call the prescriber or Poison Help at 1-800-222-1222 right away.
In the six-week trials, the most common side effects were decreased appetite, nausea, headache, trouble sleeping, dry mouth, diarrhea, stomach pain and rash. Children and teens most often had reduced appetite and rash; adults most often had headache, reduced appetite and insomnia. About 6 to 8 percent of people stopped centanafadine because of side effects, compared with about 1 percent on placebo, and rash was the most common reason. A new rash, hives, itching or peeling skin should be reported to the prescriber right away. Serious allergic reactions have occurred, though rarely. Swelling of the face, lips or throat, or trouble breathing or swallowing, is an emergency: call 911. Like other stimulants, centanafadine can raise heart rate and blood pressure. Chest pain, shortness of breath or fainting needs emergency medical care right away. Other effects are less common but worth a prompt call to the prescriber: unusually high energy, racing thoughts, or seeing or hearing things that are not there; new or worsening tics; and fingers or toes that turn pale, blue or red, feel numb or cold, or develop unexplained sores. In children, reduced appetite can add up to slower weight gain and growth over time.
Simtriyo carries two boxed warnings, the FDA's most prominent kind. The first concerns children: in a six-week study, children 6 to 12 taking centanafadine had higher rates of suicidal thoughts and behavior than those on placebo. Every child or teen taking it should be watched closely, especially in the first months. Families should call the prescriber right away about talk of suicide or dying, new or worsening depression or anxiety, or sudden changes in mood or behavior. The second concerns misuse. Like other stimulants, centanafadine can be misused and can lead to addiction, and misuse, particularly at high doses or by snorting or injecting, can cause overdose and death. The prescriber should assess this risk before starting and keep checking during treatment. Store the medicine somewhere secure, ideally locked, and never give it to anyone else. Never combine centanafadine with a monoamine oxidase inhibitor (MAOI), a class that includes some older antidepressants as well as the antibiotic linezolid and intravenous methylene blue, and wait at least 14 days after stopping an MAOI before starting it. The combination can cause dangerously high blood pressure or serotonin syndrome, an overload of serotonin activity. Serotonin syndrome can also occur when centanafadine is taken with other medicines that raise serotonin, including many antidepressants. Its signs include agitation, confusion, a fast heartbeat, sweating, fever, muscle stiffness or twitching, and seizures; if they appear, stop the medicine and get emergency care. Avoid alcohol from the time of a dose until at least two hours after it. Alcohol can make the capsule release its contents too quickly, which can increase side effects early and leave less medicine working later in the day. Centanafadine also slows the body's breakdown of some other drugs, including caffeine: in one study, the total amount of caffeine in the blood roughly doubled, so coffee may hit harder. Taking it with another stimulant adds to the rise in heart rate and blood pressure. People with serious heart disease, such as structural heart defects, cardiomyopathy, serious rhythm problems or coronary artery disease, should generally avoid it. It is not used by people with pheochromocytoma, a tumor of the adrenal gland that releases stress hormones. It can trigger mania in people with bipolar disorder and worsen existing psychotic disorders. Data in pregnancy are too limited to judge the risk, and it is not known whether it passes into breast milk. The 210 mg capsule contains the dye tartrazine (FD&C Yellow No. 5), which can cause allergic-type reactions in some people, particularly those sensitive to aspirin.
Before starting, expect questions about heart health, family history of sudden death or heart rhythm problems, mood, bipolar disorder, tics and any history of substance misuse, along with a blood pressure and pulse check. Blood pressure and heart rate are checked again after dose increases and periodically after that. A child's height and weight are tracked, and treatment may be paused if a child is not growing or gaining weight as expected. The main trials lasted six weeks. ADHD symptom scores improved more on centanafadine than on placebo, but the added benefit was modest: about 3 to 6 points on 18-item symptom scales on which people started at roughly 38 to 43, and people on placebo also improved noticeably. Those trials compared centanafadine only with placebo, so how it measures up against established ADHD medicines is not yet known. Some people were followed for a year or longer in open-label studies. Response varies, and if it does not help enough or side effects are a problem, other ADHD medicines and approaches remain options. Centanafadine is taken every day for as long as it is helping, with regular follow-up to weigh benefit against side effects. In adult studies, stopping it suddenly did not cause withdrawal symptoms beyond what people on placebo reported, but any change is still best planned with the prescriber. It has not been studied in adults 65 and older, and because it is so new there is little experience with it outside clinical trials.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Simtriyo (Centanafadine), what you've noticed, or ask the community a question.